AT
Attovia TherapeuticsAttovia Therapeutics is a clinical-stage biotech developing ATTOBODY-based biotherapeutics for immune-mediated diseases that went public on Nasdaq in August 2026 in an upsized IPO raising ~$332M gross.
8 Pulse stories
CT
Celea TherapeuticsClinical-stage biotech developing deupirfenidone, a deuterated pirfenidone-derived drug for idiopathic pulmonary fibrosis, spun out of PureTech Health.
4 Pulse stories
Total Raised
~$588M ($256M private + $332M IPO gross incl. greenshoe, Aug 2026)
$180M
Attovia TherapeuticsCelea Therapeutics
Last Valuation
$767M at IPO pricing; ~$904M market cap at Nasdaq open (Aug 5, 2026)
Attovia TherapeuticsCelea Therapeutics
Biotech
Sector
Biotech
2023
Founded
2025
San Carlos, CA
HQ
Boston, MA
Public (ATTO)
Status
Private
Attovia Therapeutics investors
venBio PartnersGoldman Sachs AlternativesFrazier Life SciencesDeep Track CapitalIllumina VenturesSanofi VenturesEcoR1 Capital
Celea Therapeutics investors
RA Capital ManagementLeaps by BayerPureTech Health
Data from Value Add Pulse coverage and company research — see the full threads for Attovia Therapeutics and Celea Therapeutics.